Status:

UNKNOWN

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Lead Sponsor:

The Alvin and Lois Lapidus Cancer Institute

Collaborating Sponsors:

Ortho Biotech Products, L.P.

Conditions:

Diffuse Large B Cell Lymphoma

Lymphoma, Non-Hodgkin

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituxi...

Detailed Description

Diffuse large B-cell lymphoma (DLBCL) is the most frequent type of non-Hodgkin's lymphoma with more than half of the patients being over the age of 60 years. Elderly patients with cancer are defined b...

Eligibility Criteria

Inclusion

  • 60 years old and older or 18 years old and older with significant/potential cardiac morbidity
  • Diagnosis of diffuse large B cell lymphoma, Ann Arbor stage I-IV, any International Prognostic Index (IPI) score.
  • Previously untreated
  • New York Heart Association (NYHA) classification of Class III or better
  • Baseline ejection fraction (EF) \> 25%
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3
  • Unless attributable to NHL: absolute neutrophil count (ANC) \> 1500/uL, platelets \> 100,000/uL; hemoglobin \> 9.0 g/dl
  • Bilirubin \< 1.5 mg/dL (unless related to lymphoma)
  • Hepatic: transaminases \< 2.5 x upper limit of normal (ULN) (unless related to lymphoma)
  • Creatinine \< 2.5 mg/dl (unless related to lymphoma)

Exclusion

  • No HIV+ individuals
  • No primary central nervous system (CNS) lymphoma
  • No pregnant or lactating women
  • No serious active infection
  • History of prior malignancy within the last 5 years other than subject's original cancer diagnosis listed in inclusion criteria with the exception of curatively treated basal cell carcinoma.

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

27 Patients enrolled

Trial Details

Trial ID

NCT00333008

Start Date

May 1 2006

Last Update

September 26 2006

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sinai Hospital of Baltimore

Baltimore, Maryland, United States, 21215

2

Northwest Hospital Center

Randallstown, Maryland, United States, 21133

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. | DecenTrialz